Geron Corporation (GERN)’s Trend Up, Especially After Today’s 52-Week High Milestone

March 21, 2018 - By Marguerite Chambers

Investors sentiment decreased to 0.97 in Q3 2017. Its down 0.24, from 1.21 in 2017Q2. It turned negative, as 10 investors sold Geron Corporation shares while 27 reduced holdings. 11 funds opened positions while 25 raised stakes. 61.75 million shares or 0.63% more from 61.36 million shares in 2017Q2 were reported.
Virtu Financial Llc invested in 0% or 104,843 shares. Pennsylvania-based Vanguard Gru has invested 0% in Geron Corporation (NASDAQ:GERN). Moreover, Millennium Limited Liability has 0% invested in Geron Corporation (NASDAQ:GERN). Amer International Gru Inc holds 0% or 99,679 shares in its portfolio. Price T Rowe Associates Md holds 109,400 shares. Pittenger And Anderson Inc has invested 0% in Geron Corporation (NASDAQ:GERN). Tudor Inv Et Al reported 0% of its portfolio in Geron Corporation (NASDAQ:GERN). Ny State Common Retirement Fund invested 0% in Geron Corporation (NASDAQ:GERN). 11,879 are held by Bluecrest Capital Management. 240,167 were accumulated by California State Teachers Retirement Sys. Aperio Gru has invested 0% in Geron Corporation (NASDAQ:GERN). Federated Investors Pa reported 0% stake. Blackrock has 0% invested in Geron Corporation (NASDAQ:GERN). Two Sigma Limited Liability Corp invested 0% in Geron Corporation (NASDAQ:GERN). Renaissance Technologies Llc owns 649,880 shares.

The stock of Geron Corporation (NASDAQ:GERN) hit a new 52-week high and has $5.17 target or 7.00 % above today’s $4.83 share price. The 8 months bullish chart indicates low risk for the $776.12 million company. The 1-year high was reported on Mar, 21 by If the $5.17 price target is reached, the company will be worth $54.33 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 15.30% or $0.641 during the last trading session, reaching $4.831. About 9.46M shares traded or 194.64% up from the average. Geron Corporation (NASDAQ:GERN) has risen 13.81% since March 21, 2017 and is uptrending. It has underperformed by 2.89% the S&P500.

Geron Corporation (NASDAQ:GERN) Ratings Coverage

Among 3 analysts covering Geron (NASDAQ:GERN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Geron had 7 analyst reports since August 8, 2015 according to SRatingsIntel. FBR Capital maintained Geron Corporation (NASDAQ:GERN) on Tuesday, September 13 with “Outperform” rating. As per Sunday, March 18, the company rating was maintained by Stifel Nicolaus. The rating was maintained by Piper Jaffray on Monday, December 7 with “Overweight”. As per Saturday, August 8, the company rating was downgraded by Zacks. Stifel Nicolaus maintained it with “Hold” rating and $2.5000 target in Tuesday, August 1 report. The company was maintained on Monday, March 19 by Piper Jaffray. On Monday, August 10 the stock rating was maintained by MLV with “Buy”.

Geron Corporation operates as a biopharmaceutical company. The company has market cap of $776.12 million. The firm supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It currently has negative earnings. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.